Glioblastoma, a highly aggressive brain tumor with diverse molecular and pathological features, poses a diagnostic challenge due to its heterogeneity. Accurate diagnosis and assessment of this heterogeneity are essential for choosing the right treatment and improving patient outcomes. Traditional methods rely on identifying specific features in tissue samples, but deep learning offers a promising approach for improved glioblastoma diagnosis. In this paper, we present our approach to the BraTS-Path Challenge 2024. We leverage a pre-trained model and fine-tune it on the BraTS-Path training dataset. Our model demonstrates poor performance on the challenging BraTS-Path validation set, as rigorously assessed by the Synapse online platform. The model achieves an accuracy of 0.392229, a recall of 0.392229, and a F1-score of 0.392229, indicating a consistent ability to correctly identify instances under the target condition. Notably, our model exhibits perfect specificity of 0.898704, showing an exceptional capacity to correctly classify negative cases. Moreover, a Matthews Correlation Coefficient (MCC) of 0.255267 is calculated, to signify a limited positive correlation between predicted and actual values and highlight our model's overall predictive power. Our solution also achieves the second place during the testing phase.